Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is a medical technology company focused on spinal fusion treatments, with a strong product portfolio of orthobiologics and spinal implants. The company has a diverse customer base and is expanding its reach, with a network of distributors and agents. The recent acquisition of Dilon Technologies and the launch of new products are expected to drive future revenue growth. Along with a competitive valuation, these factors make Xtant Medical a compelling investment opportunity.

Bears say

Xtant Medical Holdings is a medical technology company that has a major focus on designing, developing, and commercializing orthobiologics and spinal implant systems. While the company has raised its revenue guidance and achieved growth in its orthobiologics segment, there are still concerns about competition, legacy performance, the need for additional capital, and a softer-than-expected procedure environment. These factors, combined with the company's current valuation and cash flow, may limit its potential for top-line acceleration and could lead to limited upside for investors.

XTNT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 1 analysts, XTNT has a Strong Buy consensus rating as of Jul 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.